Ellen N. Behrend, VMD, MS, PhD, DACVIM

Watch the short video to hear Ellen Behrend’s, VMD, PhD, MS, DACVIM (SAIM), answer.

A small animal internist answers the question in an interview with dvm360.

Ellen Behrend, VMD, PhD, MS, DACVIM (SAIM) discusses what is currently known about remission when on SGLT2 inhibitors.

An internal medicine specialist explains the answer to this question in an interview with dvm360.

Ellen Behrend, VMD, PhD, MS, DACVIM (SAIM), discusses several advantages to using an SGLT2 inhibitor in cats compared to insulin

Ellen Behrend, VMD, PhD, MS, DACVIM (SAIM), discusses what to monitor in cats on SGLT2 inhibitors, and how it differs from the monitoring required for patients on insulin

The most common adverse effects are gastrointestinal, says Ellen Behrend, VMD, PhD, MS, DACVIM (SAIM)

Ellen Behrend, VMD, PhD, MS, DACVIM (SAIM) explains the differences between bexagliflozin and velagliflozin, and how to determine if a patient is a good candidate

Ellen Behrend, VMD, PhD, MS, DACVIM (SAIM), describes a sodium-glucose cotransporter-2 inhibitor in a dvm360 interview.

Owning a diabetic cat gave this internist additional insights into how best to manage diabetic cats at home.